UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 28, 2021

 

 

 

Gene Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-33635   27-007587

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

11230 Sorrento Valley Road, Suite 220

San Diego, California 92122

(Address of Principal Executive Offices) (Zip Code)

 

(858) 414-1477

(Registrant’s Telephone Number, Including Area Code)

 

(Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   CRXM   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 28, 2021, Murray H. Hutchison, age 82, retired from our Board of Directors after 16 years of service that commenced in 2005. Mr. Hutchison’s decision to retire was not a result of any disagreement with the Company.

 

We issued a press release relating to the resignation which is attached as Exhibit 99.1 to this report.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated July 28, 2021

 

- 2 -
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 28, 2021 GENE BIOTHERAPEUTICS, INC.
     

By: /s/ Christopher J. Reinhard
    Christopher J. Reinhard
    Chief Executive Officer

 

- 3 -

 

Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Taxus Cardium Pharmaceut... (CE) Charts.
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Taxus Cardium Pharmaceut... (CE) Charts.